Jacobio Receives CDE’s IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
Shots:
- The preclinical results showed that the combination JAB-21822 + Cetuximab can improve the anti-tumor activity of JAB-21822 in CRC tumor models, make tumor regression, and delay tumor re-growth after the cessation of using the drug
- Jacobio plans to initiate a P-I/II, open-label, multi-center, dose-escalation, and expansion clinical trial in China to assess the safety, tolerability, and preliminary efficacy of the combination therapy in KRAS G12C mutant patients with advanced CRC
- JAB-21822 is approved for 5 clinical trials in China and the US, which includes monothx and combination therapies (with either PD-1 Ab or Cetuximab) to treat KRAS G12C advanced solid tumors mutant patients including NSCLC and colorectal cancer
Ref: Businesswire | Image: Jacobio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com